Cardlytics, Inc.
No enriched coverage for $CDLX in the last 7 days.
Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.
Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.
Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million
Recent CDLX coverage spans financial news and earnings.
In the last 30 days, CDLX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($54K). The most active reporter was Gupta Amit, Chief Executive Officer, with 2 filings.
The earnings call discloses worsening top-line and user metrics, plus a Q3 billings and revenue range that frames near-term demand and partner impact.
The earnings print and forward revenue range are the primary drivers for near-term positioning in CDLX.
Q2 showed continued YoY contraction but management said it was within guidance and margins improved; the new Q3 ranges set the near-term bar for the stock.
Cardlytics has approved a reverse split and elected new directors amid ongoing financial challenges. The company's weak financial performance and bearish technicals suggest limited near-term upside, but improving cash flow and operational progress provide some optimism. Overall, the stock exhibits a neutral to slightly bearish outlook.
The CFO's purchase of 200,000 shares suggests insider confidence in Cardlytics' prospects, which could be a bullish signal for short to medium-term traders.
alphai scores every news story that mentions CDLX with an AI model for sentiment and relevance, and aggregates insider trades from Cardlytics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.
7 min readCardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.
2 min readCardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million
6 min readCardlytics (CDLX) shareholders recently approved a reverse stock split authorization, elected three Class II directors, and ratified Deloitte & Touche as the independent auditor. Despite advisory approval for executive pay, the company faces financial challenges highlighted by its "Neutral" rating from TipRanks' AI Analyst, Spark, due to weak financial performance and bearish technicals, partially offset by improving cash flow and operational progress.
3 min readCardlytics (NASDAQ: CDLX) Chief Financial Officer David Thomas Evans recently purchased 200,000 shares of the company's common stock through open-market transactions. These purchases, totaling $129,000, occurred on May 15 and May 18, 2026, at weighted average prices of $0.649 and $0.633 per share, respectively. Following these transactions, Evans directly holds 317,930 shares of Cardlytics common stock.
2 min readCardlytics Inc (CDLX) has recently experienced stock price pressure due to thin trading volumes and changing investor sentiment towards adtech and fintech hybrids. The company operates a digital advertising platform embedded in banking apps, using aggregated transaction data to offer targeted cash-back deals without personally identifiable information. Cardlytics' revenue is driven by advertising fees based on campaign performance and its partnerships with major financial institutions, positioning it as a key player at the intersection of fintech and adtech.
4 min readCardlytics, Inc. announced an inducement grant of 272,000 restricted stock units to six new employees on April 29, 2026, under the Nasdaq Listing Rule 5635(c)(4). These grants are a material inducement to employment and will vest over approximately two years, subject to continuous service. The grants were made under the Cardlytics, Inc. 2022 Inducement Plan.
2 min readCardlytics, Inc. (NASDAQ: CDLX) has filed Form 144, indicating a proposed resale of 40,296 shares of Common Stock. This resale is linked to Restricted Stock Vesting that occurred on March 31, 2026. The filing also notes a previous sale of 6,253 shares by Nicholas H. Lynton on January 5, 2026.
2 min readCardlytics (CDLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 min readCardlytics Inc. ( NASDAQ: CDLX ) saw its stock fall 9.85% during regular trading on Thursday. However, the stock rebounded in after-hours trading, climbing 5.04% to $2.50 following positive remarks from analysts. Check out the current price of CDLX stock here.
3 min read
